UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Flow and performance analysis of a natural gas-air rotating detonation engine with high-speed velocimetry

Combustion and flame, 2021-10, Vol.232 (C), p.111549, Article 111549

2021

Volltextzugriff (PDF)

Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition

Clinical cancer research, 2011-08, Vol.17 (16), p.5299-5310

2011

Volltextzugriff (PDF)

High-Speed Diagnostics in a Natural Gas–Air Rotating Detonation Engine

Journal of propulsion and power, 2020-07, Vol.36 (4), p.498-507

2020

Volltextzugriff (PDF)

Performance Characterization of a Natural Gas–Air Rotating Detonation Engine

Journal of propulsion and power, 2021-03, Vol.37 (2), p.292-304

2021

Volltextzugriff (PDF)

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC

Journal of hepatology, 2017-06, Vol.66 (6), p.1166-1172

2017

Volltextzugriff (PDF)

Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial

Hepatology (Baltimore, Md.), 2014-11, Vol.60 (5), p.1697-1707

2014

Volltextzugriff (PDF)

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

Journal of clinical oncology, 2013-10, Vol.31 (28), p.3509-3516

2013

Volltextzugriff (PDF)

Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models

International journal of molecular sciences, 2020-06, Vol.21 (12), p.4493

2020

Volltextzugriff (PDF)

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Journal of clinical oncology, 2013-10, Vol.31 (28), p.3517-3524

2013

Volltextzugriff (PDF)

Experimental validation of rotating detonation for rocket propulsion

Scientific reports, 2023-08, Vol.13 (1), p.14204-14204, Article 14204

2023

Volltextzugriff (PDF)

Operability of a Natural Gas–Air Rotating Detonation Engine

Journal of propulsion and power, 2020-05, Vol.36 (3), p.453-464

2020

Volltextzugriff (PDF)

Environmentally Friendly Boron-Based Pyrotechnic Delays: An Additive Manufacturing Approach

ACS sustainable chemistry & engineering, 2019-02, Vol.7 (4), p.4360-4367

2019

Volltextzugriff (PDF)

Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol

BMJ open, 2021-11, Vol.11 (11), p.e050725-e050725

2021

Volltextzugriff (PDF)

Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling

PloS one, 2014-04, Vol.9 (4), p.e92273

2014

Volltextzugriff (PDF)

Abstract 4007: A novel immunotherapy, INT230-6, is able to induce high rates of complete response in mice through a cytotoxic T-cell-dependent mechanism

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4007-4007

2016

Volltextzugriff (PDF)

Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma

Investigational new drugs, 2015-02, Vol.33 (1), p.247-253

2015

Volltextzugriff (PDF)

Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory

Oncoimmunology, 2019-10, Vol.8 (10), p.e1625687-e1625687

2019

Volltextzugriff (PDF)

712 IMPORT-201 (IMP-MEL): a phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist (PORT-2) and pembrolizumab for advanced melanoma and non-small cell lung cancer (NSCLC)

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A807-A807

2023

Volltextzugriff (PDF)

759 ADPORT-601 (TT-10–101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A855-A855

2023

Volltextzugriff (PDF)

Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib

American journal of hematology, 2009-10, Vol.84 (10), p.657-660

2009

Volltextzugriff (PDF)

536 Intratumoral INT230–6 shows a favorable safety profile and early signs of efficacy in advanced soft tissue sarcoma with monotherapy and in combination with ipilimumab [Intensity IT-01; BMS#CA184–592]

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A566-A566

2021

Volltextzugriff (PDF)

Correction: Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling

PloS one, 2015-11, Vol.10 (11), p.e0142355-e0142355

2015

Volltextzugriff (PDF)

411 Novel intratumoral agent, INT230–6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractory patients

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A436-A436

2020

Volltextzugriff (PDF)

Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series

Clinical advances in hematology & oncology, 2008-10, Vol.6 (10), p.755

2008

Volltextzugriff (PDF)

1 – 25 von 840

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(636)
Mit Volltextzugriff
(688)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Flow and performance analysis of a natural gas-air rotating detonation engine with high-speed velocimetry

Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition

High-Speed Diagnostics in a Natural Gas–Air Rotating Detonation Engine

Performance Characterization of a Natural Gas–Air Rotating Detonation Engine

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC

Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Experimental validation of rotating detonation for rocket propulsion

Operability of a Natural Gas–Air Rotating Detonation Engine

Environmentally Friendly Boron-Based Pyrotechnic Delays: An Additive Manufacturing Approach

Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type K-RAS Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial

Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol

Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling

Abstract 4007: A novel immunotherapy, INT230-6, is able to induce high rates of complete response in mice through a cytotoxic T-cell-dependent mechanism

Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma

Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory

712 IMPORT-201 (IMP-MEL): a phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist (PORT-2) and pembrolizumab for advanced melanoma and non-small cell lung cancer (NSCLC)

759 ADPORT-601 (TT-10–101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors

Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib

536 Intratumoral INT230–6 shows a favorable safety profile and early signs of efficacy in advanced soft tissue sarcoma with monotherapy and in combination with ipilimumab [Intensity IT-01; BMS#CA184–592]

Correction: Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling

411 Novel intratumoral agent, INT230–6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractory patients

Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series

Suchergebnisse filtern